Non-Hodgkin's lymphoma is a type of cancer that affects the lymphatic system, which is a part of the body's immune system. It is the most common type of lymphoma, accounting for about 4% of all cancer cases worldwide. The prevalence of Non-Hodgkin's lymphoma varies across different regions and populations. In the United States, it is estimated that there will be around 81,560 new cases of Non-Hodgkin's lymphoma in 2021. The incidence of this cancer has been increasing over the past few decades, but advancements in treatment have also improved survival rates.
Non-Hodgkin's lymphoma (NHL) is a type of cancer that affects the lymphatic system, which is a part of the body's immune system. It is characterized by the abnormal growth of lymphocytes, a type of white blood cell. NHL is the most common type of lymphoma, accounting for about 90% of all cases.
The prevalence of NHL varies across different populations and regions. According to global cancer statistics, the estimated number of new cases of NHL worldwide in 2020 was around 509,590. This represents approximately 2.7% of all new cancer cases. The incidence of NHL has been increasing over the past few decades, although the rate of increase has slowed down in recent years.
Several factors contribute to the development of NHL, including age, gender, genetic predisposition, immune system disorders, exposure to certain chemicals or radiation, and infections such as the Epstein-Barr virus and human immunodeficiency virus (HIV).
Early detection and advancements in treatment options have improved the prognosis for NHL patients. However, it is still important to raise awareness about the signs and symptoms of NHL to ensure timely diagnosis and appropriate management. Regular medical check-ups and maintaining a healthy lifestyle can also help reduce the risk of developing NHL.